Literature DB >> 25503720

[Indications for nephron-sparing surgery. Analysis over a 13-year period in the context of changing guidelines].

P J Olbert1, M Maier, H Heers, A Hegele, R Hofmann.   

Abstract

BACKGROUND: The indications for nephron-sparing surgery have been considerably extended by guideline recommendations in recent years. It remains unclear whether clinical practice still reflects these new guidelines.
OBJECTIVE: In this retrospective, monocentric analysis at a tertiary referral center the indications for partial nephrectomy over a 13-year period were evaluated.
METHODS: In a retrospective database analysis all cases of surgically treated renal masses from 2001 to 2013 were evaluated. Besides demographic, tumor-specific and perioperative variables the development of the surgical technique depending on the tumor stage was evaluated. RESULTS AND DISCUSSION: The proportion of nephron-sparing surgery cases increased from below 20 % in 2001 to 35 % in 2013 in the entire cohort. For stage T1a tumors, partial nephrectomy increased from approximately 50 % to over 90 % and for T1b tumors it rose from 10 % to 50 %. Logistic regression revealed stage 1 tumors to be predictive of partial nephrectomy over the complete evaluation period. Extending the indications for partial nephrectomy even to higher stages is under discussion but not yet supported by data from prospective, controlled studies.

Entities:  

Mesh:

Year:  2015        PMID: 25503720     DOI: 10.1007/s00120-014-3710-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  17 in total

1.  A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors:  Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

2.  Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version?

Authors:  Sandra Waalkes; Frank Becker; Andres J Schrader; Martin Janssen; Gerd Wegener; Axel S Merseburger; Mark Schrader; Rainer Hofmann; Michael Stöckle; Markus A Kuczyk
Journal:  Eur Urol       Date:  2010-10-15       Impact factor: 20.096

3.  Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort.

Authors:  Simon P Kim; Angela L Alt; Christopher J Weight; Brian A Costello; John C Cheville; Christine Lohse; Cristine Allmer; Bradley C Leibovich
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

4.  Global increases in kidney cancer incidence, 1973-1992.

Authors:  A Mathew; S S Devesa; J F Fraumeni; W-H Chow
Journal:  Eur J Cancer Prev       Date:  2002-04       Impact factor: 2.497

5.  Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy.

Authors:  Jens Hansen; Maxine Sun; Marco Bianchi; Michael Rink; Zhe Tian; Nawar Hanna; Malek Meskawi; Jan Schmitges; Shahrokh F Shariat; Felix K-H Chun; Paul Perrotte; Markus Graefen; Pierre I Karakiewicz
Journal:  Urology       Date:  2012-06-13       Impact factor: 2.649

6.  Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.

Authors:  Jens Bedke; Stephan Buse; Maria Pritsch; Stephan Macher-Goeppinger; Peter Schirmacher; Axel Haferkamp; Markus Hohenfellner
Journal:  BJU Int       Date:  2008-12-08       Impact factor: 5.588

7.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

8.  Partial and radical nephrectomy provide comparable long-term cancer control for T1b renal cell carcinoma.

Authors:  Malek Meskawi; Andreas Becker; Marco Bianchi; Quoc-Dien Trinh; Florian Roghmann; Zhe Tian; Markus Graefen; Paul Perrotte; Pierre I Karakiewicz; Maxine Sun
Journal:  Int J Urol       Date:  2013-07-02       Impact factor: 3.369

9.  Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score.

Authors:  Ryan P Kopp; Reza Mehrazin; Kerrin L Palazzi; Michael A Liss; Ramzi Jabaji; Hossein S Mirheydar; Hak J Lee; Nishant Patel; Fuad Elkhoury; Anthony L Patterson; Ithaar H Derweesh
Journal:  BJU Int       Date:  2014-10-03       Impact factor: 5.588

10.  Obesity and renal cell cancer--a quantitative review.

Authors:  A Bergström; C C Hsieh; P Lindblad; C M Lu; N R Cook; A Wolk
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

View more
  1 in total

Review 1.  [Focal therapy for small renal masses : Observation, ablation or surgery].

Authors:  J J Wendler; B Friebe; D Baumunk; A Blana; T Franiel; R Ganzer; B Hadaschik; T Henkel; K U Köhrmann; J Köllermann; T Kuru; S Machtens; A Roosen; G Salomon; H P Schlemmer; L Sentker; U Witzsch; U B Liehr; J Ricke; M Schostak
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.